Document:

Exhibit 10.57

MOMENTA PHARMACEUTICALS, INC.

Executive Retention Agreement

THIS
EXECUTIVE RETENTION AGREEMENT by and between Momenta Pharmaceuticals, Inc., a
Delaware corporation (the “Company”), and
[     ] (the “Executive”) is effective as of
the date of the last signature on the signature page attached hereto (the “Effective
Date”).

WHEREAS,
the Company recognizes that, as is the case with many publicly-held
corporations, the possibility of a change in control of the Company exists and
that such possibility, and the uncertainty and questions which it may raise
among key personnel, may result in the departure or distraction of key
personnel to the detriment of the Company and its stockholders, and

WHEREAS,
the Board of Directors of the Company (the “Board”) has determined that
appropriate steps should be taken to reinforce and encourage the continued
employment and dedication of the Company’s key personnel without distraction
from the possibility of a change in control of the Company and related events
and circumstances.

NOW,
THEREFORE, as an inducement for and in consideration of the Executive remaining
in [his/her] employ, the Company
agrees that the Executive shall receive the severance benefits set forth in
this Agreement in the event the Executive’s employment with the Company is
terminated under the circumstances described below subsequent to a Change in
Control (as defined in Section 1.1).

1.             Key Definitions.

As
used herein, the following terms shall have the following respective meanings:

1.1           “Change
in Control” means an event or occurrence set forth in any one or more of
subsections (a) through (d) below (including an event or occurrence that
constitutes a Change in Control under one of such subsections but is
specifically exempted from another such subsection)

(a)           the acquisition by an individual, entity or
group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”)) (a “Person”)
of beneficial ownership of any capital stock of the Company if, after such
acquisition, such Person beneficially owns (within the meaning of Rule 13d-3
promulgated under the Exchange Act) 50% or more of either (x) the
then-outstanding shares of common stock of the Company (the “Outstanding
Company Common Stock”) or (y) the combined voting power of the
then-outstanding securities of the Company entitled to vote generally in the
election of directors (the “Outstanding Company Voting Securities”); provided,
however, that for purposes of this subsection (a), the following
acquisitions shall not constitute a Change in Control: (i) any acquisition
directly from the Company (excluding an acquisition pursuant to the exercise,
conversion or exchange of any security exercisable for, convertible into or
exchangeable for common stock or voting securities of the Company, unless the
Person exercising, converting or exchanging such security acquired such
security directly from the Company or an underwriter or agent of the Company),
(ii) any acquisition by the Company, (iii) any acquisition by any employee
benefit plan (or related trust) sponsored or maintained by the Company or any
corporation controlled by the Company, or (iv) any acquisition by any
corporation pursuant to a transaction which complies with clauses (i) and (ii)
of subsection (c) of this Section 1.1; or

(b)           such time as the Continuing Directors (as
defined below) do not constitute a majority of the Board (or, if applicable,
the Board of Directors of a successor corporation to the Company), where the
term “Continuing Director” means at any date a member of the  Board (i) who was a member of the Board on
the date of the execution of this Agreement or (ii) who was nominated or
elected subsequent to such date by at least a majority of the directors who
were Continuing Directors at the time of such nomination or election or whose
election to the Board was recommended or endorsed by at least a majority of the
directors who were Continuing Directors at the

time of such nomination or election; provided,
however, that there shall be excluded from this clause (ii) any
individual whose initial assumption of office occurred as a result of an actual
or threatened election contest with respect to the election or removal of
directors or other actual or threatened solicitation of proxies or consents, by
or on behalf of a person other than the Board; or

(c)           the consummation of a merger, consolidation,
reorganization, recapitalization or statutory share exchange involving the
Company or a sale or other disposition of all or substantially all of the
assets of the Company in one or a series of transactions (a “Business
Combination”), unless, immediately following such Business Combination,
each of the following two conditions is satisfied: (i) all or substantially all
of the individuals and entities who were the beneficial owners of the
Outstanding Company Common Stock and Outstanding Company Voting Securities
immediately prior to such Business Combination beneficially own, directly or
indirectly, more than 50% of the then-outstanding shares of common stock and
the combined voting power of the then-outstanding securities entitled to vote
generally in the election of directors, respectively, of the resulting or
acquiring corporation in such Business Combination (which shall include, without
limitation, a corporation which as a result of such transaction owns the
Company or substantially all of the Company’s assets either directly or through
one or more subsidiaries) (such resulting or acquiring corporation is referred
to herein as the “Acquiring Corporation”) in substantially the same
proportions as their ownership, immediately prior to such Business Combination,
of the Outstanding Company Common Stock and Outstanding Company Voting
Securities, respectively; and (ii) no Person (excluding any employee benefit
plan (or related trust) maintained or sponsored by the Company or by the
Acquiring Corporation) beneficially owns, directly or indirectly, 50% or more
of the then outstanding shares of common stock of the Acquiring Corporation, or
of the combined voting power of the then-outstanding securities of such
corporation entitled to vote generally in the election of directors (except to
the extent that such ownership existed prior to the Business Combination); or

(d)           approval by the stockholders of the Company
of a complete liquidation or dissolution of the Company.

1.2           “Change
in Control Date” means the first date during the Term (as defined in
Section 2) on which a Change in Control occurs.  Anything in this Agreement to the contrary
notwithstanding, if (a) a Change in Control occurs, (b) the Executive’s
employment with the Company is terminated prior to the date on which the Change
in Control occurs, and (c) it is reasonably demonstrated by the Executive
that such termination of employment (i) was at the request of a third party who
has taken steps reasonably calculated to effect a Change in Control or (ii)
otherwise arose in connection with or in anticipation of a Change in Control,
then for all purposes of this Agreement the “Change in Control Date” shall mean
the date immediately prior to the date of such termination of employment.

1.3           “Cause”
means (a) a good faith finding by no fewer than two-thirds of the members of
the Board (excluding the Executive, if applicable) of (i) the Executive’s failure
to (1) perform reasonably assigned lawful duties or (2) comply with a lawful
instruction of the Board, Chief Executive Officer or such other executive
officer with direct supervisory authority over the Executive so long as, in the
case of (2), the instruction is consistent with the scope and responsibilities
of the Executive’s position, or (ii) the Executive’s dishonesty, willful
misconduct or gross negligence, or (iii) the Executive’s substantial and
material failure or refusal to perform according to, or to comply with, the
policies, procedures or practices established by the Company or the Board and,
in the case of (i) or (iii), the Executive has had ten (10) days written notice
to cure his failure to so perform or comply; or (b) the Executive’s indictment,
or the entering of a guilty plea or plea of “no contest” with respect to a
felony or any crime involving moral turpitude.

1.4           “Good
Reason” means the occurrence, without the Executive’s written consent, of
any of the events or circumstances set forth in clauses (a) through (d) below, provided,
however, that an event described in clauses (a) through (d) below shall
not constitute Good Reason unless it is communicated in writing in accordance
with Section 7, within 90 days of the event giving rise to the claim, by the
Executive to the Board or its successor and unless it is not corrected by the
Company or its successor and the Executive has not been reasonably compensated
for any loss or damages resulting therefrom within thirty (30) days of the Company’s
receipt of such written notice:

(a)           the assignment to the Executive of duties
inconsistent in any material respect with the Executive’s position (including
status, offices, titles and reporting requirements), authority or
responsibilities,

or any other action or omission by the
Company which results in a material diminution in such position, authority or
responsibilities;

(b)           the Board requiring the Executive to engage
in unlawful conduct;

(c)           a material reduction in the Executive’s base
salary; or

(d)           a change by the Company in the location at
which the Executive performs [his/her]
principal duties for the Company to a new location that is both (i) outside a
radius of 50 miles from the Executive’s principal residence and (ii) more than
30 miles from the location at which the Executive performed his principal
duties for the Company.

The  Executive’s right
to terminate [his/her] employment for Good
Reason shall not be affected by [his/her]
incapacity due to physical or mental illness.

1.5           “Disability”
means the Executive’s absence from the full-time performance of the Executive’s
duties with the Company for 180 consecutive calendar days as a result of
incapacity due to mental or physical illness which is determined to be total
and permanent by a physician selected by the Company or its insurers and
acceptable to the Executive or the Executive’s legal representative.

2.             Term of Agreement.  This Agreement, and all rights and
obligations of the parties hereunder, shall take effect upon the Effective Date
and shall expire upon the first to occur of (a) the expiration of the Term (as
defined below) if a Change in Control has not occurred during the Term, (b) the
termination of the Executive’s employment with the Company prior to the Change
in Control Date, (c) the date 12 months after the Change in Control Date,
if the Executive is still employed by the Company as of such later date, or (d)
the fulfillment by the Company of all of its obligations under Sections 4
and 5.2 if the Executive’s employment with the Company terminates within 12  months following the Change in Control Date.  “Term” shall mean the period
commencing as of the Effective Date and continuing in effect through December
31, 2007;  provided, however,
that commencing on January 1, 2008 and each January 1 thereafter, the Term
shall be automatically extended for one additional year unless, not later than
90 days prior to the scheduled expiration of the Term (or any extension
thereof), the Company shall have given the Executive written notice that the Term
will not be extended, except as otherwise provided pursuant to Section 1.2.

3.             Employment Status; Termination Following
Change in Control.

3.1           Not
an Employment Contract.  The Executive acknowledges that this
Agreement does not constitute a contract of employment or impose on the Company
any obligation to retain the Executive as an employee and that this Agreement
does not prevent the Executive from terminating employment at any time.  If the Executive’s employment with the
Company terminates for any reason and subsequently a Change in Control shall
occur, the Executive shall not be entitled to any benefits hereunder.

3.2           Termination
of Employment.

(a)           If
the Change in Control Date occurs during the Term, any termination of the
Executive’s employment by the Company or by the Executive within 12 months
following the Change in Control Date (other than due to the death of the
Executive) shall be communicated by a written notice to the other party hereto
(the “Notice of Termination”), given in accordance with Section 7.  Any Notice of Termination shall: (i) indicate
the specific termination provision (if any) of this Agreement relied upon by
the party giving such notice, (ii) to the extent applicable, set forth in reasonable
detail the facts and circumstances claimed to provide a basis for termination
of the Executive’s employment under the provision so indicated and (iii)
specify the Date of Termination (as defined below).  The effective date of an employment
termination (the “Date of Termination”) shall be the close of business
on the date specified in the Notice of Termination (which date may not be less
than 15 days or more than 120 days after the date of delivery of such Notice of
Termination), in the case of a termination other than one due to the Executive’s
death, or the date of the Executive’s death, as the case may be.  In the event the Company fails to satisfy the
requirements of Section 3.2(a) regarding a Notice of Termination, the purported
termination of the Executive’s employment pursuant to such Notice of
Termination shall not be effective for purposes of this Agreement.

(b)           The
failure by the Executive or the Company to set forth in the Notice of
Termination any fact or circumstance which contributes to a showing of Good
Reason or Cause shall not waive any right of the Executive or the Company,
respectively, hereunder or preclude the Executive or the Company, respectively,
from asserting any such fact or circumstance in enforcing the Executive’s or
the Company’s rights hereunder.

4.             Benefits to Executive.

4.1           Stock
Acceleration.  If the Change in Control Date occurs during
the Term and the Executive’s employment with the Company is terminated by the
Company (other than for Cause, Disability or death) or by the Executive for
Good Reason within 12 months following the Change in Control, then,
effective upon the Date of Termination, each outstanding award then held by the
Executive under the Company’s outstanding equity incentive plans shall become
immediately exercisable in full, shall become immediately realizable or
deliverable, or restrictions applicable to each such award shall lapse
immediately, as applicable.

4.2           Compensation.  If
the Change in Control Date occurs during the Term and the Executive’s
employment with the Company terminates within 12 months following the Change in
Control Date, the Executive shall be entitled to the following benefits:

(a)           Termination Without Cause or for Good
Reason.  If the Executive’s
employment with the Company is terminated by the Company (other than for Cause,
Disability or death) or by the Executive for Good Reason within 12 months
following the Change in Control Date, then the Executive shall be entitled to
the following benefits:

(i)            the Company shall pay to the Executive in a
lump sum in cash within 30 days after the Date of Termination the aggregate of
the following amounts:

(1)           the sum of (A) the Executive’s base
salary through the Date of Termination and (B) any accrued vacation pay to
the extent not previously paid (the sum of the amounts described in clauses (A)
and (B) shall be hereinafter referred to as the “Accrued Obligations”); and

(2)           the sum of (A) the amount equal to the
Executive’s annual base salary during the one year period prior to the Date of
Termination and (B) the greater
of (x) the target bonus established by the Board (or any other person or
persons having authority with respect thereto) for the Executive for the fiscal
year in which the Date of Termination occurs and (y) the annual bonus paid to
the Executive for the most recently completed fiscal year.

(ii)           For 12 months after the Date of Termination,
or such longer period as may be provided by the terms of the appropriate plan,
program, practice or policy, the Company shall continue to provide benefits to
the Executive and the Executive’s family at least equal to those which would
have been provided to them if the Executive’s employment had not been
terminated, in accordance with the applicable life insurance, medical, dental,
health and accident and disability plans in effect immediately prior to the
Date of Termination or, if more favorable to the Executive and [his/her] family, in effect generally at any time
thereafter with respect to other peer executives of the Company and its
affiliated companies; provided, however, that if the Executive becomes
reemployed with another employer and is eligible to receive a particular type
of benefits (e.g., health insurance benefits) from such employer on terms at
least as favorable to the Executive and [his/her] family as
those being provided by the Company, then the Company shall no longer be
required to provide those particular benefits to the Executive and [his/her] family. 
At the end of such 12 month period, the Executive may continue such
plans on [his/her] own behalf or pursuant to COBRA, if applicable,
and shall be responsible for all premiums thereafter;

(iii)          to the extent not previously paid or
provided, the Company shall timely pay or provide to the Executive any other
amounts or benefits required to be paid or provided or which the Executive is
eligible to receive following the Executive’s termination of employment under
any plan, program, policy, practice, contract or agreement of the Company and
its affiliated companies (such other amounts and benefits shall be hereinafter
referred to as the “Other Benefits”); and

(iv)          for purposes of determining eligibility (but
not the time of commencement of benefits) of the Executive for retiree benefits
to which the Executive is entitled, the Executive shall be considered to have
remained employed by the Company until 12 months after the Date of Termination.

(b)           Resignation
without Good Reason; Termination for Death or Disability.  If
the Executive voluntarily terminates [his/her] employment
with the Company within 12 months following the Change in Control Date,
excluding a termination for Good Reason, or if the Executive’s employment with
the Company is terminated by reason of the Executive’s death or Disability
within 12 months following the Change in Control Date, then the Company shall
(i) pay the Executive (or [his/her] estate, if applicable), in a lump sum in
cash within 30 days after the Date of Termination, the Accrued Obligations and
(ii) timely pay or provide to the Executive the Other Benefits.

(c)           Termination
for Cause.  If the Company terminates the Executive’s
employment with the Company for Cause within 12 months following the Change in
Control Date, then the Company shall (i) pay the Executive, in a lump sum
in cash within 30 days after the Date of Termination, the Accrued Obligations
and (ii) timely pay or provide to the Executive the Other Benefits.

4.3           Taxes.

(a)           Notwithstanding any other provision of this Agreement, except as set
forth in Section 4.3(b), in the event that the Company undergoes a  “Change in Ownership or Control” (as defined
below), the Company shall not be obligated to provide to the Executive a
portion of any “Contingent Compensation Payments” (as defined below) that the
Executive would otherwise be entitled to receive to the extent necessary to
eliminate any “excess parachute payments” (as defined in Section 280G(b)(1) of
the Internal Revenue Code of 1986, as amended (the “Code”)) for the
Executive.  For purposes of this
Section 4.3, the Contingent Compensation Payments so eliminated shall be
referred to as the “Eliminated Payments” and the aggregate amount (determined
in accordance with Proposed Treasury Regulation Section 1.280G-1, Q/A-30 or any
successor provision) of the Contingent Compensation Payments so eliminated
shall be referred to as the “Eliminated Amount.”

(b)           Notwithstanding the provisions of Section 4.3(a), no such reduction in
Contingent Compensation Payments shall be made if (i) the Eliminated Amount
(computed without regard to this sentence) exceeds (ii) 110% of  the aggregate
present value (determined in accordance with Proposed Treasury Regulation
Section 1.280G-1, Q/A-31 and Q/A-32 or any successor provisions) of the
amount of any additional taxes that would be incurred by the Executive if the
Eliminated Payments (determined without regard to this sentence) were paid to [him/her] (including, state and federal income taxes on the
Eliminated Payments, the excise tax imposed by Section 4999 of the Code payable
with respect to all of the Contingent Compensation Payments in excess of the
Executive’s “base amount” (as defined in Section 280G(b)(3) of the Code), and
any withholding taxes).  The override of
such reduction in Contingent Compensation Payments pursuant to this
Section 4.3(b) shall be referred to as a “Section 4.3(b) Override.”  For purpose of this paragraph, if any federal
or state income taxes would be attributable to the receipt of any Eliminated
Payment, the amount of such taxes shall be computed by multiplying the amount
of the Eliminated Payment by the maximum combined federal and state income tax
rate provided by law.

(c)           For purposes of this Section 4.3 the following terms shall have the
following respective meanings:

(i)            “Change in Ownership or Control” shall mean a
change in the ownership or effective control of the Company or in the ownership
of a substantial portion of the assets of the Company determined in accordance
with Section 280G(b)(2) of the Code.

(ii)         “Contingent Compensation Payment” shall mean
any payment (or benefit) in the nature of compensation that is made or made
available (under this Agreement or otherwise) to a “disqualified individual”
(as defined in Section 280G(c) of the Code) and that is contingent (within the
meaning of Section 280G(b)(2)(A)(i) of the Code) on a Change in Ownership or
Control of the Company.

(d)         Any payments or other benefits otherwise due to the Executive following
a Change in Ownership or Control that could reasonably be characterized (as
determined by the Company) as Contingent Compensation Payments (the “Potential
Payments”) shall not be made until the dates provided for in this
Section 4.3(d).  Within 30 days
after each date on which the Executive first becomes entitled to receive
(whether or not then due) a Contingent Compensation Payment relating to such
Change in Ownership or Control, the Company shall determine and notify the
Executive (with reasonable detail regarding the basis for its determinations)
(i) which Potential Payments constitute Contingent Compensation Payments, (ii)
the Eliminated Amount and (iii) whether the Section 4.3(b) Override
is applicable.  Within 30 days after
delivery of such notice to the Executive, the Executive shall deliver a
response to the Company (the “Executive Response”) stating either (A)
that [he/she] agrees with the Company’s
determination pursuant to the preceding sentence, in which case 

[he/she] shall
indicate, if applicable, which Contingent Compensation Payments, or portions
thereof (the aggregate amount of which, determined in accordance with Proposed
Treasury Regulation Section 1.280G-1, Q/A-30 or any successor provision, shall
be equal to the Eliminated Amount), shall be treated as Eliminated Payments or
(B) that [he/she] disagrees with such
determination, in which case [he/she] shall
set forth (i) which Potential Payments should be characterized as Contingent
Compensation Payments, (ii) the Eliminated Amount, (iii) whether the
Section 4.3(b) Override is applicable, and (iv) which (if any) Contingent
Compensation Payments, or portions thereof (the aggregate amount of which,
determined in accordance with Proposed Treasury Regulation Section 1.280G-1,
Q/A-30 or any successor provision, shall be equal to the Eliminated Amount, if
any), shall be treated as Eliminated Payments. 
In the event that the Executive fails to deliver an Executive Response
on or before the required date, the Company’s initial determination shall be
final and the Contingent Compensation Payments that shall be treated as
Eliminated Payments shall be determined by the Company in its absolute
discretion.  If the Executive states in the
Executive Response that [he/she]
agrees with the Company’s determination, the Company shall make the Potential
Payments to the Executive within three business days following delivery to the
Company of the Executive Response (except for any Potential Payments which are
not due to be made until after such date, which Potential Payments shall be
made on the date on which they are due). 
If the Executive states in the Executive Response that [he/she] disagrees with the Company’s determination, then,
for a period of 60 days following delivery of the Executive Response, the
Executive and the Company shall use good faith efforts to resolve such
dispute.  If such dispute is not resolved
within such 60-day period, such dispute shall be settled exclusively by
arbitration in Boston, Massachusetts, in accordance with the rules of the
American Arbitration Association then in effect.  Judgment may be entered on the arbitrator’s
award in any court having jurisdiction. 
The Company shall, within three business days following delivery to the
Company of the Executive Response, make to the Executive those Potential
Payments as to which there is no dispute between the Company and the Executive
regarding whether they should be made (except for any such Potential Payments
which are not due to be made until after such date, which Potential Payments
shall be made on the date on which they are due).  The balance of the Potential Payments shall
be made within three business days following the resolution of such
dispute.  Subject to the limitations
contained in Sections 4.3(a) and (b) hereof, the amount of any payments to be
made to the Executive following the resolution of such dispute shall be
increased by amount of the accrued interest thereon computed at the prime rate
announced from time to time by The Wall
Street Journal, compounded monthly from the date that such payments
originally were due.

(e)           The provisions of this Section 4.3 are intended to apply to any and all
payments or benefits available to the Executive under this Agreement or any
other agreement or plan of the Company under which the Executive receives
Contingent Compensation Payments.

4.4           Mitigation.  The
Executive shall not be required to mitigate the amount of any payment or
benefits provided for in this Section 4 by seeking other employment or
otherwise. Further, except as provided in Section 4.2(a)(ii), the amount of any
payment or benefits provided for in this Section 4 shall not be reduced by any
compensation earned by the Executive as a result of employment by another employer,
by retirement benefits, by offset against any amount claimed to be owed by the
Executive to the Company or otherwise.

5.             Disputes.

5.1           Settlement
of Disputes; Arbitration.  All claims by the Executive for benefits
under this Agreement shall be directed to and determined by the Board of
Directors of the Company and shall be in writing.  Any denial by the Board of Directors of a
claim for benefits under this Agreement shall be delivered to the Executive in
writing and shall set forth the specific reasons for the denial and the
specific provisions of this Agreement relied upon.  The Board of Directors shall afford a
reasonable opportunity to the Executive for a review of the decision denying a
claim.  Any further dispute or
controversy arising under or in connection with this Agreement shall be settled
exclusively by arbitration in Boston, Massachusetts, in accordance with the
rules of the American Arbitration Association then in effect.  Judgment may be entered on the arbitrator’s
award in any court having jurisdiction.

5.2           Expenses.  The
Company agrees to pay as incurred, to the full extent permitted by law, all
legal, accounting and other fees and expenses which the Executive may
reasonably incur as a result of any claim or contest (regardless of the outcome
thereof) by the Company, the Executive or others regarding the validity or
enforceability of, or liability under, any provision of this Agreement or any
guarantee of performance thereof (including as a result of any contest by the
Executive regarding the amount of any payment or benefits pursuant to this
Agreement), plus in each case interest on any delayed payment at the applicable
Federal rate provided for in Section 7872(f)(2)(A) of the Code.

6.             Successors.

6.1           Successor
to Company.  The Company shall require any successor
(whether direct or indirect, by purchase, merger, consolidation or otherwise)
to all or substantially all of the business or assets of the Company expressly
to assume and agree to perform this Agreement to the same extent that the
Company would be required to perform it if no such succession had taken
place.  Failure of the Company to obtain
an assumption of this Agreement at or prior to the effectiveness of any
succession shall be a breach of this Agreement and shall constitute Good Reason
if the Executive elects to terminate employment, except that for purposes of
implementing the foregoing, the date on which any such succession becomes
effective shall be deemed the Date of Termination.  As used in this Agreement, “Company” shall
mean the Company as defined above and any successor to its business or assets
as aforesaid which assumes and agrees to perform this Agreement, by operation
of law or otherwise.

6.2           Successor
to Executive.  This Agreement shall inure to the benefit of
and be enforceable by the Executive’s personal or legal representatives,
executors, administrators, successors, heirs, distributees, devisees and
legatees.  If the Executive should die
while any amount would still be payable to the Executive or [his/her] family hereunder if the Executive
had continued to live, all such amounts, unless otherwise provided herein,
shall be paid in accordance with the terms of this Agreement to the executors,
personal representatives or administrators of the Executive’s estate.

7.             Notice.  All notices, instructions and
other communications given hereunder or in connection herewith shall be in
writing.  Any such notice, instruction or
communication shall be sent either (i) by registered or certified mail, return
receipt requested, postage prepaid, or (ii) prepaid via a reputable nationwide
overnight courier service, in each case addressed to the Company, at 675 West
Kendall Street, Cambridge, Massachusetts 02142, and to the Executive at the
Executive’s address indicated on the signature page of this Agreement (or to
such other address as either the Company or the Executive may have furnished to
the other in writing in accordance herewith). 
Any such notice, instruction or communication shall be deemed to have
been delivered five business days after it is sent by registered or certified
mail, return receipt requested, postage prepaid, or one business day after it
is sent via a reputable nationwide overnight courier service. Either party may
give any notice, instruction or other communication hereunder using any other
means, but no such notice, instruction or other communication shall be deemed
to have been duly delivered unless and until it actually is received by the
party for whom it is intended.

8.             Miscellaneous.

8.1           Employment
by Subsidiary.  For purposes of this Agreement, the Executive’s
employment with the Company shall not be deemed to have terminated solely as a
result of the Executive continuing to be employed by a wholly-owned subsidiary
of the Company.

8.2           Severability.  The invalidity
or unenforceability of any provision of this Agreement shall not affect the
validity or enforceability of any other provision of this Agreement, which
shall remain in full force and effect.

8.3           Injunctive
Relief.  The Company and the Executive agree that any
breach of this Agreement by the Company is likely to cause the Executive
substantial and irrevocable damage and therefore, in the event of any such
breach, in addition to such other remedies which may be available, the
Executive shall have the right to specific performance and injunctive relief.

8.4           Governing
Law.  The validity, interpretation, construction
and performance of this Agreement shall be governed by the internal laws of the
Commonwealth of Massachusetts, without regard to conflicts of law principles.

8.5           Waivers.  No
waiver by the Executive at any time of any breach of, or compliance with, any
provision of this Agreement to be performed by the Company shall be deemed a
waiver of that or any other provision at any subsequent time.

8.6           Counterparts.  This
Agreement may be executed in counterparts, each of which shall be deemed to be
an original but both of which together shall constitute one and the same
instrument.

8.7           Tax
Withholding.  Any payments provided for hereunder shall be
paid net of any applicable tax withholding required under federal, state or
local law.

8.8           Entire
Agreement.  This Agreement sets forth the entire
agreement of the parties hereto in respect of the subject matter contained
herein and supersedes all prior agreements, promises, covenants, arrangements,
communications, representations or warranties, whether oral or written, by any
officer, employee or representative of any party hereto in respect of the
subject matter contained herein; and any prior agreement of the parties hereto
in respect of the subject matter contained herein is hereby terminated and
cancelled.

8.9           Section
409A.  No payments that may be made pursuant to this
Agreement that constitute “nonqualified deferred compensation” within the
meaning of Section 409A of the Internal Revenue Code and the guidance issued
thereunder (“Section 409A”) may be accelerated or deferred by the Company or
the Executive.  Notwithstanding anything
else to the contrary in this Agreement, to the extent that any of the payments
to be made hereunder constitute “nonqualified deferred compensation” within the
meaning of Section 409A and the Executive is a “specified employee,” then upon [his /her] termination (as defined under Section 409A),
any such payment shall be delayed until the date that is six months and one day
following the Date of Termination if, absent such delay, such payment would
otherwise be subject to penalties under Section 409A.  In any event, the Company makes no representation
or warranty and shall have no liability to the Executive or any other person if
any provisions of this Agreement are determined to constitute deferred
compensation subject to Section 409A but do not satisfy the conditions of such
section.

8.10         Amendments.  This
Agreement may be amended or modified only by a written instrument executed by
both the Company and the Executive.

8.11         Executive’s
Acknowledgements.  The Executive acknowledges that [he/she]: (a) has read this Agreement; (b) has been
represented in the preparation, negotiation, and execution of this Agreement by
legal counsel of the Executive’s own choice or has voluntarily declined to seek
such counsel; (c) understands the terms and consequences of this Agreement; and
(d) understands that the law firm of WilmerHale is acting as counsel to the
Company in connection with the transactions contemplated by this Agreement, and
is not acting as counsel for the Executive.

IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day
and year first set forth above.

	
  

  	
  MOMENTA PHARMACEUTICALS, INC.

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  Title:

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  Date:

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  [NAME OF EXECUTIVE]

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  Signature:

  	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  Address:

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  Date:Exhibit
10.31

CONFIDENTIAL
TREATMENT REQUESTED

EXCLUSIVE
DISTRIBUTION AGREEMENT

Agreement dated January, 1st 2002 between Bruker BioSpin GmbH, having its
principal place of business at Rheinstetten, Germany (the “Manufacturer”) and
Bruker Optics Inc., a Delaware corporation, having its principal place of
business at Billerica, Massachusetts (the “Distributor”).

WHEREAS, Manufacturer is engaged in the business of
manufacturing analytical instrumentation for Quality Control based on the
principle of TD (time domain)-NMR the Product (as hereinafter defined);

WHEREAS, Distributor is engaged in the business of
selling and marketing goods manufactured. 
by others in the Territory (as hereinafter defined); and

WHEREAS, Distributor is desirous of being appointed an
exclusive distributor of the Product in the Territory.

NOW, THEREFORE, in consideration of the mutual
covenants and agreements herein contained, Manufacturer and Distributor hereby
agree as follows:

1.             DEFINITIONS

                1.1           Product.  The term “Product” shall mean Manufacturer’s
product known as the TD-NMR Analyzer “the-minispec.”

                1.2           Territory.  The term “Territory” shall mean the all
countries of the world.

2.             EXCLUSIVE DISTRIBUTORSHIP

Manufacturer
hereby grants to Distributor the exclusive right to sell the Product during the
Term (as hereinafter defined) to customers within the Territory for delivery in
the Territory, all in accordance with the terms and conditions set forth
herein.

3.             ORDERS AND PERFORMANCE

Distributor shall
place orders for the Product with Manufacturer setting forth the quantity of
the Product ordered and the desired delivery date.  Manufacturer, after its acknowledgment and
acceptance of the order, shall sell the Product to Distributor for resale in the
Territory.  No order shall be binding
unless acknowledged and accepted in writing by Manufacturer.  Manufacturer shall confirm its acceptance or
rejection of an order within fifteen (15) days after its actual receipt of such
order.  The terms and conditions of sale
shall be those set forth in this Agreement and Exhibit A, and any
terms set forth in Distributor’s order shall be of no force or effect.  The Product sold to Distributor by
Manufacturer shall be shipped F.O.B. Manufacturer’s plant to the destination of
the Distributor.  Distributor shall pay
all freight insurance, duty and customs, and any other charge associated with
shipment or import of the Product.

CONFIDENTIAL
TREATMENT REQUESTED

 

4.             PRICE AND PAYMENT

                4.1           Prices.  The prices for the Product shall be as
established by Manufacturer from time to time. 
Prices shall be subject to change by Manufacturer from time to time by
thirty (30) days’ prior written notice to Distributor; provided, however, that
no such price change shall affect orders accepted by Manufacturer prior to
notifying Distributor of such price change. 
All prices are exclusive of all import duties and governmental excise,
sales, use, occupational or similar taxes.

                4.2   Terms of Payment.  Payment shall be made by Distributor
separately for each order accepted by Manufacturer by cash remittance to be
made by Distributor to Manufacturer payable no later than thirty (30) days
after delivery to the F.O.B. point.

5.             MARKETING AND ADVERTISING

                5.1           Distributor’s Undertaking.  Distributor shall exert its best efforts to
promote the sale of the Product in the Territory and to develop a market demand
for the same in the Territory.

                5.2           Right to Appoint Sub Dealers.  Distributor shall have the right, at its own
discretion, to appoint a sub-dealer or sub-dealers to exploit the Product in
the Territory in accordance with the grant of the distributorship pursuant to
Section 2 above; provided that any sub-dealer shall only sell the Product
to end-user customers and not to any third party for the purpose of resale by
such third party.

                5.3           Sales Materials.  Manufacturer will provide Distributor, at no
cost to Distributor, such sales materials with respect to the Product as
Manufacturer generally makes available to its distributors, including technical
specifications, prices, drawings, advertisements and samples, and Distributor
may reproduce such materials as reasonably required, provided that all
copyright, trademark and other property markings are reproduced.  All such materials remain the property of
Manufacturer and, except as they are distributed by Distributor in the course
of its performance of its duties under this Agreement, must be promptly
returned to Manufacturer upon the expiration or termination of this Agreement.

                5.4   Trade Fairs and Exhibitions.  Distributor will participate in trade fairs
and exhibitions to market the Product in the Territory.

6.             CONFIDENTIALITY

Distributor shall
hold in strict confidence and shall not disclose to others or use, either
before or after termination or expiration of this Agreement, any technical or
business information, manufacturing technique, process, experimental work,
trade secret or other confidential matter relating to the Product, except to
the extent disclosure is reasonably required in connection with Distributor’s
proper marketing activities in the Territory. 
Distributor shall, upon request (and upon termination or expiration of
this Agreement without request), deliver to Manufacturer any and all drawings,
notes, documents and materials received from Manufacturer.  

 2
 

CONFIDENTIAL
TREATMENT REQUESTED

 

Distributor shall not, directly or indirectly, attempt
to reverse engineer, reverse assemble or otherwise try to discover the
formulation of the Product.

7.             WARRANTY

Manufacturer
grants to Distributor the warranty with respect to the Product set forth in
paragraph 4 of Exhibit A. 
Distributor shall have the right to resell the Product with such
warranty.  Manufacturer will be
responsible for satisfying such warranty so long as the same has not been amended
or extended by Distributor.  Manufacturer
will not assume any other responsibility for the Product after the Product has
been received by Distributor.

8.             LIMITATION OF LIABILITY

Except as provided
in paragraph 5 of Exhibit A, the liability of Manufacturer for
any claim arising out of or in connection with this Agreement shall not exceed
the amount paid to Manufacturer by Distributor with respect to the sale of the
specific Product cited in such claim.  In
no event shall Manufacturer have any liability for incidental, indirect,
consequential, special or punitive damages.

9.             RELATIONSHIP OF PARTIES

Nothing contained
in this Agreement shall be construed to constitute Distributor as a partner,
employee or agent of Manufacturer, nor shall Distributor hold itself out as
such.  Distributor has no right or
authority to incur, assume or create, in writing or otherwise, any warranty,
liability or other obligation of any kind, express or implied, in the name of
or on behalf of Manufacturer, it being intended by both Distributor and
Manufacturer that each shall remain an independent contractor responsible for
its own actions.

10.           ASSIGNMENT

Distributor shall
not assign, transfer or otherwise dispose of this Agreement in whole or in part
without the prior written consent of Manufacturer.

11.           TERM OF AGREEMENT

This Agreement
shall remain in effect for a period of five (5) years after the date hereof
(the “Term”), provided that this Agreement is not earlier terminated under
Section 12 hereof.  At expiration of
5  years the contract extends one year at
a time.

Upon any
expiration or termination of this Agreement, Sections 4.2, 6 and 8, and
Paragraph 4 of Exhibit A shall remain in full force and effect.

 

 

 3
 

CONFIDENTIAL
TREATMENT REQUESTED

 

12.           TERMINATION.

12.1         Events of
Termination.

(i)            Either
party may gives the other party written notice of its intension that this
agreement shall not continue in force and effect for the next year.  Any such notice shall be given at least 12
months prior to the expiration of the term in effect.

(ii)           Bankruptcy,
etc.  Immediately upon written notice
to the other party in the event that proceedings in bankruptcy or insolvency
are instituted by or against the other party, or a receiver is appointed, or if
any substantial part of the assets of the other party is the object of
attachment, sequestration or other type of comparable proceeding, and such
proceeding is not vacated or terminated within thirty (30) days after its
commencement or institution; or

(iii)          Default.  If one party commits a material breach of any
of the terms or provisions of this Agreement and does not cure such breach
within thirty (30) days after receipt of written notice given by the other
party.

                12.2         Rights Upon Termination.  Upon termination of this Agreement, by
expiration of the Term or otherwise, all further rights and obligations of the
parties shall cease except as set forth in Section 11 and except that the
parties shall not be relieved of (i) Distributor’s obligations to pay any
moneys due or which become due as of or subsequent to the date of termination,
and (ii) Manufacturer’s obligation to fulfill any order accepted by
Manufacturer prior to the effective date of termination or expiration of the
Term.  No consideration or indemnity
shall be payable to Distributor either for loss of profit, goodwill, creation of
clientele or other like or unlike items, nor for advertising costs, costs of
samples or supplies, termination of employees, employees’ salaries and other
like or unlike items.

13.           MISCELLANEOUS.

13.1         Force
Majeure.  If the performance of any
obligation under this Agreement is prevented, restricted or interfered with by
reason of war, revolution, civil commotion, acts of public enemies, blockade,
embargo, strikes, any law, order, proclamation, regulation, ordinance, demand,
or requirement having a legal effect of any government or any judicial authority
or representative of any such government, or any other act whatsoever, whether
similar or dissimilar to those referred to in this Section 13.1, which is
beyond the reasonable control of the party affected, then the party so affected
shall, upon giving prior written notice to the other party, be excused from
such performance to the extent of such prevention, restriction, or
interference, provided that the party so affected shall use reasonable
commercial efforts to avoid or remove such causes of nonperformance, and shall
continue performance hereunder with reasonable dispatch whenever such causes
are removed.

13.2         Entire
Agreement.  This Agreement
constitutes the entire agreement between the parties hereto and supersedes all
previous negotiations, agreements and 

 4
 

CONFIDENTIAL
TREATMENT REQUESTED

 

commitments with respect thereto, and shall not be
released, discharged, changed or modified in any manner except by instruments
signed by duly authorized officers or representatives of each of the parties hereto.

13.3         Applicable
Law.  Any claim or controversy
relating in any way to this Agreement shall be governed and interpreted
exclusively in accordance with the laws of The Commonwealth of Massachusetts.

13.4         Partial
Illegality.  If any provision of this
Agreement or the application thereof to any party or circumstances shall be
declared void, illegal or unenforceable, the remainder of this Agreement shall
be valid and enforceable to the extent permitted by applicable law.  In such event, the parties shall use their
best efforts to replace the invalid or unenforceable provision by a provision
that, to the extent permitted by the applicable law, achieves the purposes
intended under the invalid or unenforceable provision.  Any deviation by either party from the terms
and provisions of this Agreement in order to comply with applicable laws, rules
or regulations shall not be considered a breach of this Agreement.

13.5         Waiver
of Compliance.  Any failure by any
party hereto to enforce at any time any term or condition under this Agreement
shall not be considered a waiver of that party’s right thereafter to enforce
each and every term and condition of this Agreement.

13.6         Notices.  All notices and other communications in
connection with this Agreement shall be in writing and shall be sent to the
respective parties at the following addresses, or to such other addresses as
may be designated by the parties in writing from time to time in accordance
with this Section 13.6, by certified air mail, postage prepaid, or by express
courier service, service fee prepaid.

	
  

  	
  TO MANUFACTURER:

  	
  Bruker BioSpin GmbH

  
	
   

  	
   

  	
  Silberstreifen

  
	
   

  	
   

  	
  76287
  Rheinstetten

  
	
   

  	
   

  	
  Attention:
  Managing Director

  
	
   

  	
   

  	
   

  
	
   

  	
  TO DISTRIBUTOR:

  	
  Bruker Optics Inc.

  
	
   

  	
   

  	
  19 Fortune Drive

  
	
   

  	
   

  	
  Billerica, MA
  01821

  
	
   

  	
   

  	
  Attention: President

  

 

All notices shall be
deemed received (i) if given by hand, immediately, (ii) if given by
air mail, three (3) business days after posting, or (iii) if given by
express courier service, the next business day in the jurisdiction of the
recipient.

13.7         Counterparts.  This Agreement may be executed in
counterparts, each of which shall be deemed to be an original and all of which
together shall be deemed to be one and the same instrument.

 5
 

CONFIDENTIAL
TREATMENT REQUESTED

 

IN WITNESS WHEREOF, the parties have caused this
Agreement to be executed as of the date hereof

	
  BRUKER OPTICS INC.

  	
  BRUKER BIOSPIN GmbH

  
	
   

  	
   

  
	
  By: 

  	
  /s/ Dirk D.
  Laukien

  	
   

  	
  By:

  	
  /s/ Dieter Schmalbein

  
	
   

  	
  Name: Dr. Dirk
  Laukien

  	
   

  	
  Name: Dr. Dieter Schmalbein

  
	
   

  	
  Title: President

  	
   

  	
  Title: Managing Director

  
					

 

 6

CONFIDENTIAL
TREATMENT REQUESTED

 

EXHIBIT A

TERMS AND
CONDITIONS

1.             ACCEPTANCE OF ORDERS

Orders shall not be binding upon Manufacturer until
accepted in writing by an authorized representative of Manufacturer.

2.             DELIVERY

Shipping dates are approximate and deliveries are
subject to unavoidable delays. 
Manufacturer shall have the right to deliver all Product at one time or
in installments from time to time within the time of delivery herein provided.

3.             ACCEPTANCE OF GOODS

The Product shall be inspected upon tender to
Distributor.  Failure to inspect within
ten (10) days after tender shall constitute a waiver of Distributor’s rights of
inspection and shall be equivalent to acceptance of the Product.  Distributor will pay all costs of inspection.

4.             WARRANTY

Manufacturer warrants that the Product shall be free
from defects in material and workmanship under normal use and service for
ninety (90) days from date of shipment.

Written notice and an explanation of the circumstances
of any claim that the Product has proved defective in material or workmanship
shall be given promptly by Distributor to Manufacturer.  DISTRIBUTOR’S SOLE AND EXCLUSIVE REMEDY IN
THE EVENT OF ANY DEFECT IS EXPRESSLY LIMITED TO THE CORRECTION OF SUCH DEFECT
OR REPLACEMENT OF THE DEFECTIVE PRODUCT BY MANUFACTURER AT ITS ELECTION AND
SOLE EXPENSE, EXCEPT THAT THERE SHALL BE NO OBLIGATION TO REPLACE OR REPAIR
ITEMS WHICH BY THEIR NATURE ARE EXPENDABLE. 
If Manufacturer is unable to replace or repair the defective Product,
Manufacturer shall refund to Distributor that portion of the purchase price
allocable to such Product.

No representation or other affirmation of fact not set
forth herein, including, but not limited to, statements regarding capacity,
suitability for use, or performance of the Product, shall be or be deemed to be
a warranty or representation by Manufacturer for any purpose, nor give rise to
any liability or obligation of Manufacturer whatever.

EXCEPT AS SPECIFICALLY PROVIDED IN THIS DOCUMENT,
THERE ARE NO OTHER WARRANTIES EXPRESSED OR IMPLIED, INCLUDING, BUT NOT LIMITED
TO, ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURCHASE.

CONFIDENTIAL
TREATMENT REQUESTED

 

5.             DEFENSE
OF INFRINGEMENT CLAIMS

If notified promptly in writing of any action (and all
prior claims relating to such action) brought against Distributor based on a
claim that Distributor’s use of the Product infringes a patent or other
intellectual property right, and if given access by Distributor to any
information Distributor has regarding such alleged infringement, Manufacturer
will defend Distributor in such action at its expense and will pay any costs or
damages finally awarded against Distributor in any such action, provided the
Manufacturer shall have had sole control of the defense of any such action and
all negotiations for its settlement or compromise.  In the event that a final injunction shall be
obtained against Distributor’s use of the Product by reason of infringement of
a patent or other intellectual property right or if in Manufacturer’s opinion
the Product is likely to become the subject of a claim of infringement of a
patent or other intellectual property right, Manufacturer will, at its option
and at its expense, either procure for Distributor the right to continue using
the Product, replace or modify the same so it becomes non infringing or grant
Distributor a credit for such Product as depreciated and accept its
return.  The depreciation shall be an
equal amount per year over the five (5) year lifetime of the Product.  Manufacturer shall not have any liability to
Distributor under any provision of this clause if any infringement, or claim
thereof, is based upon:  (i) the use
of the Product in combination with other products or devices which are not made
by Manufacturer, (ii) the use of the Product in practicing any process,
(iii) the furnishing to Distributor of any information, data, service or
applications assistance, or (iv) the use of the Product with modifications
made by Distributor.  No costs or
expenses shall be incurred for the account of Manufacturer without the written
consent of Manufacturer.  THE FOREGOING
STATES THE ENTIRE LIABILITY OF MANUFACTURER WITH RESPECT TO INFRINGEMENT OF
PATENTS OR OTHER INTELLECTUAL PROPERTY RIGHT BY THE PRODUCT OR BY ITS USE.

6.             TRANSFER PRICES MANUFACTURER TO
DISTRIBUTOR

The Manufacturer delivers the Products based on an OEM
price list.  The OEM price list is
reviewed once per year in the beginning of an New Year.  On an average the transfer prices should not
exceed [ * ] % of the sales price to the
customer in the Territory.

 

 

 

 

 

 

 

[ * ]         Indicates
information has been omitted and separately filed with the Securities and
Exchange Commission  pursuant to an
application for an order declaring confidential treatment thereof.

 2

CONFIDENTIAL
TREATMENT REQUESTED

 

AMENDMENT

Amendment dated April 17, 2006 between Broker BioSpin
GmbH, having its principal place of business in Rheinstetten, Germany (the “Manufacturer”)
and Bruker Optics Inc., a Delaware corporation having its principal place of
business in Billerica, Massachusetts (the “Distributor”)

WITNESSETH:

WHEREAS, the Manufacturer and the Distributor are
parties to a certain Exclusive Distribution Agreement dated January 1, 2002
(the “Agreement”); and

WHEREAS, the parties hereto desire to amend the
Agreement in certain respects;

NOW, THEREFORE, in consideration of the foregoing and
other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the Manufacturer and the Distributor hereby amend the
Agreement by deleting the first paragraph of text of Section 11 of the
Agreement and substituting therefor the following:

This Agreement shall
remain in effect for a period of nine (9) years after the date hereof (the “Term”),
provided that this Agreement is not earlier terminated under Section 12
hereof.  Upon the expiration of such nine
(9) year period, this Agreement shall automatically extend for a series of
successive one (1) year terms unless terminated by either party by notice to the
other party at least ninety (90) days prior to any renewal date.

IN WITNESS WHEREOF, the parties hereto have executed
this Amendment in duplicate originals as of the date first written above.

	
  BRUKER BIOSPIN GMBH

  	
   

  	
  BRUKER OPTICS INC.

  
	
   

  	
   

  	
   

  
	
  By:

  	
  /s/ Dieter Schmalbein

  	
   

  	
  By:

  	
  /s/ Dirk D. Laukien

  
	
   

  	
   

  	
   

  
	
  Title: Managing Director

  	
   

  	
  Title: President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}]]